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Characterization of the mechanism(s) of action of trans-acting factors in higher eukaryotes requires the
establishment of cellular models that test their function at endogenous target gene regulatory elements.
Erythroid Kru¨ppel-like factor (EKLF) is essential for -globin gene transcription. To elucidate the in vivo
determinants leading to transcription of the adult -globin gene, functional domains of EKLF were examined
in the context of chromatin remodeling and transcriptional activation at the endogenous locus. Human EKLF
(hEKLF) sequences, linked to an estrogen-responsive domain, were studied with an erythroblast cell line
lacking endogenous EKLF expression (J2eeklf). J2eeklf cells transduced with hEKLF demonstrated a
dose-dependent rescue of -globin transcription in the presence of inducing ligand. Further analysis using a
series of amino-terminal truncation mutants of hEKLF identified a distinct internal domain, which is sufficient
for transactivation. Interestingly, studies of the chromatin structure of the -promoter revealed that a smaller
carboxy-terminal domain generated an open promoter configuration. In vitro and in vivo binding studies
demonstrated that this region interacted with BRG1, a component of the SWI/SNF chromatin remodeling
complex. However, further study revealed that BRG1 interacted with an even smaller domain of EKLF,
suggesting that additional protein interactions are required for chromatin remodeling at the endogenous
-promoter. Taken together, our findings support a stepwise process of chromatin remodeling and coactivator
recruitment to the -globin promoter in vivo. The J2eeklf inducible hEKLF system will be a valuable tool for
further characterizing the temporal series of events required for endogenous -globin gene transcription.
Appropriate control of gene transcription demands that a
series of coordinated interactions occur between tissue-re-
stricted and ubiquitously expressed transactivators, chromatin
remodeling complexes, coactivators, and the general transcrip-
tional machinery (38, 45). Although reconstitution studies of in
vitro-chromatinized and nonchromatinized templates have re-
vealed key interactions in this process, less is known about the
molecular events required for gene transcription in vivo, par-
ticularly at mammalian gene loci. In this context, regulation of
the five structural genes of the murine -globin multigene
cluster (5-εy-h0-h1-maj-min-3) provides a suitable mod-
el for studying these events given their tissue-specific and de-
velopmentally specific pattern of expression (20, 25, 51). Al-
though a powerful upstream enhancer, the locus control region
is required for high-level tissue-specific expression (28, 33),
and the determinants of developmentally specific expression
reside in gene-proximal promoter and enhancer sequences (18,
26, 41, 46).
Several cis-acting elements that modulate developmentally
specific gene expression have been identified in -globin-like
gene promoters (14, 36, 53, 63). Of these, the proximal -glo-
bin CACC motif is a particularly attractive candidate for study,
a thalassemic state being observed in individuals with point
mutations in this element (53). This alteration disrupts specif-
ically the binding of an erythroid-specific transactivator, ery-
throid Kru¨ppel-like factor (EKLF) (27, 49). The critical non-
redundant role of EKLF in adult erythroid cells was further
emphasized in gene disruption studies of the murine homo-
logue. EKLF null embryos die with a lethal anemia at day 14 to
15 of gestation, definitive erythroid cells failing to produce
maj transcripts (52, 58). Further study of these deficient em-
bryos revealed a specific loss of a developmentally specific
DNase I hypersensitivity site in the proximal -globin pro-
moter of day 14 erythroblasts derived from EKLF null embryos
(57, 72). Since the degree of DNase I hypersensitivity of a given
locus correlates with nucleosomal remodeling (56, 65, 68),
these findings support the contention that EKLF is required
for chromatin reorganization at the -globin promoter in de-
finitive erythroid cells.
The molecular mechanism by which EKLF modulates chro-
matin structure at the -globin promoter has been examined in
chromatin reconstitution assays (4, 37). A highly purified SWI/
SNF-containing multiprotein complex, E-RC1, purified from
murine erythroid cells, interacts with the Kru¨ppel-like C2H2-
type zinc finger COOH-terminal DNA binding domain of re-
combinant EKLF. This interaction results in remodeling and
activation of a chromatinized -globin promoter template.
SWI/SNF complexes have been implicated in remodeling nu-
cleosomes in an ATP-dependent manner in many eukaryotic
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organisms, permitting increased access of trans-acting factors
to their cognate binding sites (40, 61, 67). Although subunit
heterogeneity is a characteristic of SWI/SNF complexes puri-
fied from different cell types (69, 70), a minimum catalytic core
of three components, BRG1, INI1, and BAF155 or BAF170,
is sufficient to remodel nucleosomal arrays in vitro (37, 62).
Interestingly, a direct protein-protein interaction between
BRG1, the critical ATPase component of E-RC1, and the
DNA binding domain of EKLF has been defined, this interac-
tion being sufficient for in vitro remodeling of a chromatinized
-globin template (37).
The complexity of EKLF function is further emphasized by
a review of prior structure-function studies. Initial studies of
the proline-rich NH2-terminal domain of EKLF suggested that
the first 102 amino acids mediate transactivation, an internal
domain mediating transcriptional repression in these assays
(11). However, subsequent studies utilizing transient -pro-
moter reporter assays have demonstrated that an internal, as
yet uncharacterized domain of EKLF is sufficient for transac-
tivation (54). Taken together, these studies raise the question
of the role, necessity, and sufficiency of the domains of EKLF
for transcriptional initiation at the endogenous -globin pro-
moter. Our ability to address these issues has been facilitated
by the recent description of erythroid cell lines derived from
EKLF null murine fetal liver erythroblasts, transformed with a
raf/myc-containing retrovirus (15). Introduction of the murine
EKLF cDNA into these cells by retrovirally mediated gene
transfer resulted in rescue of human -globin gene expression.
Utilizing this resource, we have determined systematically that
separate domains of EKLF subserve chromatin remodeling
and transactivation functions at the endogenous murine -glo-
bin promoter. Our studies provide evidence that EKLF-cofac-
tor interactions, in addition to that involving E-RC1, may be
required to achieve the open chromatin configuration and ini-
tiation of transcription required at the -globin promoter in
definitive erythroid cells.
MATERIALS AND METHODS
Plasmid constructions. pSP-HA-fIEKLF was constructed by fusing a double-
stranded oligonucleotide encoding consensus Kozak and influenza virus hemag-
glutinin (HA) tag sequences in frame with the human EKLF open reading frame
utilizing the pSP-hEKLF plasmid (66). pSP-HA-164 EKLF was prepared by
inserting the 1,196-bp BstXI (blunt)-XhoI fragment of pSP-hEKLF into
Ecl136II-XhoI sites of pSP-HA-210. pSP-HA-221EKLF was made by inserting
the 1,025-bp SacII (blunt)-XhoI fragment of pSP-hEKLF into the Ecl136II and
XhoI sites of pSP-HA-210. pSP-HA-253EKLF was made by inserting the
899-bp PstI (blunt)-SalI fragment of pSPhEKLF into the Ecl136II and XhoI sites
of pSp-HA-210. pSP-HA-210 has the above-described HA oligonucleotide se-
quence inserted in the EcoRI site of the pSP73 polylinker (a kind gift of Derek
Persons). The eukaryotic expression plasmids used in transient-transfection stud-
ies were generated by subcloning the EKLF fragment of each of the above pSP
constructs into pCINeo (Promega). Glutathione S-transferase (GST) fusion con-
structs were generated by subcloning the EKLF fragment of the above pSP
constructs into pGEX-4T-1 (Amersham Pharmacia). The retroviral vector con-
structs used in transduction of J2eeklf cells were generated by subcloning the
EKLF fragment of the above pSP constructs into pMSCV-ER-irGFP vector (15).
All constructs were sequenced to verify in-frame fusion with the HA, GST, and
estrogen receptor (ER) domains, respectively.
The plasmids pBJ5-BRG1 and pDNBRG1 were kind gifts of G. Crabtree and
R. Kingston, respectively (35, 39). The pBJ5 BRG1 plasmid was made by a
frameshift at amino acid 78 of BRG1. A 1,240-bp PstI kanamycin resistance
cassette (pUC4K; Amersham Pharmacia Biotech) was inserted into the NsiI site
of pBJ5 BRG1, resulting in complete loss of the BRG1 protein as determined by
Western analysis (data not shown). The T7 polymerase expression plasmid of
BRG1 was generated by inserting the 5,350-bp SgrAI (blunt)-MunI (blunt) frag-
ment of pBJ5 BRG1 into the SmaI site of pSP73 (Promega). The MSCV-
DNBRG1-irYFP vector was made by inserting the DNBRG1 coding sequence
into the pMSCV-ER-irYFP vector. The pMSCV-ER-irYFP vector is a derivative
vector in which the enhanced yellow fluorescent protein (irYFP; Clontech)
coding sequence replaces the irGFP cDNA in the pMSCV-ER-irGFP vector.
Cell culture. K562 human erythroleukemia cells, SW13 human adrenal carci-
noma cells, and 293T fibroblast cells were maintained in Dulbecco’s modified
Eagle’s medium (DMEM) (Bio Whittaker) with 100 U of penicillin/ml and 0.1
mg of streptomycin (Pen/Strep; Bio Whittaker)/ml and 10% fetal bovine serum
(Bio Whittaker). The EKLF-null erythroid cell line B1 (15) was maintained in
Dulbecco’s modified Eagle’s medium with Pen/Strep and 15% fetal bovine serum
(Bio Whittaker). Cells were cultured at 37°C in a humidified atmosphere with
5% CO2.
J2eeklf transductions and analysis. Amphotropic retroviral supernatants
were generated to transduce J2eeklf cells in a manner described previously (59).
Briefly, 293T cells were cotransfected with appropriate pMSCV-flEKLF-irGFP
constructs with the helper plasmid pEQPAM3 (59). Typical transfections gen-
erated titers of 105 infectious particles/ml. Viral supernatants for each con-
struct were used repeatedly (three to six times) to transduce 5  104 J2eeklf
cells. Transduced cells were allowed to recover and then expanded over 3 to
4 days in J2e growth media. The top 5 to 10% green fluorescent protein (GFP)-
expressing fraction was selected by fluorescence-activated cell sorting (FACS),
expanded, and re-sorted by FACS until 90% of the population was GFP.
Each GFP pool was assessed by Southern blotting to have stable, intact retro-
viral sequence (data not shown), and the presence of equivalent levels of
EKLF-ER protein in the nucleus after tamoxifen induction was verified by
Western blotting.
For nuclear localization study, nuclear extracts were prepared as described
previously (2) with minor modification, using 107 J2eeklf cells induced with 100
nM tamoxifen. Equal amounts of total protein were subjected to sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and Western analysis
utilizing a polyclonal anti-estrogen receptor antiserum (Santa Cruz) and ECL
development kit according to the manufacturer’s protocol (Amersham). Blots
were stripped and reprobed with p38 antisera (Santa Cruz) as a control. The
electrophoretic mobility shift assays (EMSA) were performed as described pre-
viously (19), using equal protein concentrations of each purified GST-EKLF
recombinant and a CACC motif containing 32P-labeled probe.
Secondary transduction of J2eeklf flEKLF with DN-BRG1 was achieved by
transducing J2eeklf flEKLF with VSV-G viral supernatants encoding dominant-
negative (DN)-BRG1. Viral supernatants were generated using 293T cells as
described above. The top 5 to 10% YFP-expressing fraction was selected by
FACS, expanded, and re-sorted for the YFP GFP phenotype by FACS until
93% of the population was YFP GFP. The YFP GFP pool was assessed
to have stable, intact retroviral sequences by Southern blotting and to express
DN-BRG1-ER and EKLF-ER protein after tamoxifen induction by Western
blotting (data not shown).
DNase I hypersensitivity assays. Cell cultures of approximately 0.4  106 cells
per ml of J2eeklf cells were set up in duplicate. Tamoxifen (Sigma) at a final
concentration of 100 nM or an equivalent diluent control was added to the
induced and uninduced cultures, respectively. After 36 h of growth, nuclei from
approximately 108 cells were prepared and analyzed as described previously (71).
Briefly, aliquots of nuclei were digested with increasing amounts of DNase I
(Pharmacia) for 10 min at 37°C. One aliquot was incubated without addition of
DNase I to serve as a control for endogenous nuclease activity. The reactions
were stopped with a twofold volume of 250 g of of proteinase K (Promega)/ml,
10 mM NaCl, 0.5% SDS, 10 mM EDTA, and 10 mM Tris (pH 8.0) and incubated
at 55°C for 16 h. After phenol-chloroform extraction, approximately 12 g of
DNA was digested with the restriction enzyme indicated in the text, separated on
a 1% agarose gel, and transferred to a nylon membrane by Southern blotting.
Analysis of DNase I hypersensitivity was performed utilizing maj-specific (34)
or aminolevulinate synthase (ala-s)-specific probes (64).
RNase protection analysis. Total RNA was extracted from approximately
1.5  107 cells, cultured in a manner similar to that described for DNase I
hypersensitivity assays, utilizing the STAT 60 reagent (Ambion). RNase protec-
tion assays (RPA) were performed utilizing an RPA II kit (Ambion) and 32P-
labeled riboprobes specific for murine , h1, and maj riboprobes (6, 50).
Briefly, approximately 106 cpm of each riboprobe was added to 2 g of total
RNA and allowed to anneal at 42°C overnight. After RNase digestion, the
protected fragments were separated on a 6% denaturing polyacrylamide gel and
visualized using a Molecular Dynamics PhosphorImager (Amersham Pharmacia
Biotech).
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Transient-transfection studies. K562 cells were transfected using a Bio-Rad
Gene Pulser apparatus as described previously (36). Immediately following the
transfection, 20 mM hemin (Sigma) was added to the growth media. SW13 cells
were transfected by lipofection following the manufacturer’s protocol (Fugene6;
Roche). Plasmid concentrations, optimized for the transfection studies de-
scribed, were 10 g of appropriate pCIneo construct, 5 g of appropriate
pBRG1 construct (as indicated in the text), 2 g of HS2luc (36), and 0.2 g of
TK-Renilla luciferase plasmid (Promega). The TK-Renilla luciferase plasmid
was utilized to correct results for transfection efficiency. After 48 h posttrans-
fection, cell lysates for each cell line were prepared and tested for luciferase
activity using the Dual Luciferase Reporter Assay System (Promega). Luciferase
activity was quantitated on a Monolight 2001 luminometer (Analytical Lumines-
cence Laboratories). The results are a summary of at least three experiments in
which each construct was tested in duplicate.
In vitro binding assays. GST fusion proteins were generated for each pGST-
EKLF construct as previously described with minor modifications (73). Briefly,
expression of GST fusion proteins was induced by culturing logarithmically
growing transformed BL21(pLysS) Escherichia coli cells (Stratagene) in the pres-
ence of 0.5 mM isopropyl--D-thiogalactopyranoside (Sigma) for 1.5 to 3 h.
Pellets from a 500-ml culture were resuspended in 12.5 ml of TSE (50 mM
Tris-HCl [pH 8], 25% sucrose, 1 mM EDTA). TSE buffer and subsequent buffers
contained a cocktail of protease inhibitors (Protease Inhibitor Cocktail Tablets;
Roche). The bacterial suspension was incubated at room temperature for 5 min
in the presence of 5 mg of lysozyme/ml. The lysate was supplemented with 10
mM MgCl2, 10 mM MnCl2, and 10 g of DNase I/ml and incubated for 15 min
at 37°C. The lysate was further supplemented with 2 ml of 10 phosphate-
buffered saline (PBS), 1 ml of 20% Tween 20, 1 ml of 20% Triton X-100, 0.2 ml
of 1 M dithiothreitol, and additional protease inhibitors. Extracts were centri-
fuged for 20 min at 12,500 rpm in a Sorvall SS-34 rotor. Supernatants were
diluted 1:1 in PBS wash (PBS plus 5 mM EDTA, 1 mM -mercaptoethanol, and
1% Triton X-100) and were rocked with 0.5 ml of a 50% slurry of preequilibrated
glutathione Sepharose (Amersham Pharmacia) at 4°C. After an overnight bind-
ing reaction, the beads were washed sequentially with 10 ml of the following: PBS
wash, PBS wash with 0.5 M NaCl, PBS with 0.5% sodium deoxycholate, and PBS
wash with 0.05 M NaCl.
For GST chromatography assays, 35S-labeled recombinant protein was gener-
ated in vitro using the pSP-BRG1 construct and the TNT translation system and
following the manufacturer’s protocol (Promega). GST fusion protein beads
were washed twice with PC-100 (20 mM HEPES [pH 7.9], 100 mM KCl, 0.2 mM
EDTA, 5 mM MgCl2, 0.1% NP-40, 20% glycerol, 0.1 mg of bovine serum
albumin/ml, 1 mM dithiothreitol, and a protease cocktail [Roche]) and pre-
blocked with 30 l of normal rabbit serum in 1 ml of PC-100 for 5 min. The beads
were washed twice with PC-200 (PC-100 buffer, except with 200 mM KCl) and
were typically incubated with 2.5 l of 35S-labeled protein in 50 l of PC-200 for
30 min. The Sepharose beads were washed three times with the PC buffer,
containing the KCl salt concentration described in the text. The washed beads
were boiled in 30 l of 2 SDS-PAGE sample buffer. Eluted proteins were
analyzed via SDS-PAGE and autoradiography (Molecular Dynamics Phosphor-
Imager; Amersham Pharmacia).
In vivo binding studies. Immunoprecipitation assays were done essentially as
described previously (24). SW13 cells were transfected (Fugene6; Roche) with 3
g of EKLF, EKLF mutant, or parent HA-tagged expression vector and 5 g of
BRG1 expression vector. Cells were harvested 48 h later in lysis buffer containing
300 mM KCl. Precleared lysates were immunoprecipitated with monoclonal
anti-HA antibody (Roche). Precipitates were washed three times and subjected
to SDS-PAGE and immunoblotting with a BRG1-specific antiserum (BJ2; a kind
gift from G. Crabtree).
RESULTS
Human EKLF activates the endogenous murine -globin
promoter. To explore the determinants of EKLF-dependent
-globin gene activation in vivo, we utilized a J2eeklf ery-
throid cell line (clone B1), derived previously from erythro-
blasts of an EKLF null embryo (15). As observed in murine
EKLF studies, J2eeklf cells transduced by a human EKLF
retrovirus showed altered growth and viability (15; also data
not shown). These findings, coupled with studies of EKLF
activity in transgenic mice (47), suggest that the level of EKLF
alters cellular homeostasis, potentially through aberrant ex-
pression of -globin chains. To test if titration of EKLF would
alleviate toxicity and correlate with -globin transcription, we
developed a ligand-inducible system to control human EKLF
expression in J2eeklf cells. Utilizing a murine stem cell virus
(MSCV)-based retroviral vector system, we prepared viral su-
pernatants for MSCV-EKLFirGFP and MSCV-irGFP. The
MSCV-EKLFirGFP retrovirus contains full-length hEKLF
cDNA (flEKLF) fused in frame with the influenza virus HA
epitope at the NH2-terminal and tamoxifen-binding domain of
the mutant ER at the COOH terminal (Fig. 1A). This chimeric
sequence is linked by an internal ribosomal entry site (ir) to
sequences encoding the enhanced GFP marker. The irGFP
construct that lacks EKLF sequences served as a control. Am-
photropic retroviral supernatants were generated in standard
fashion (see Materials and Methods) and used to transduce
FIG. 1. Exogenous expression of human EKLF-ER rescues -glo-
bin expression in J2eeklf null cells. The coding region of hEKLF was
fused in frame to the tamoxifen response element ER in a retroviral
GFP cloning vector (see Materials and Methods). Viral supernatants
were used to transduce the hEKLF-ER sequence into J2eeklf cells. A
pool of GFP cells was selected by FACS and then characterized for
hEKLF expression and function. (A) Schematic of the retroviral con-
struct utilized to test hEKLF function in J2eeklf cells. Note that the
hEKLF cDNA was fused in frame with an HA epitope tag at the NH2
terminus to facilitate immunological detection and with the ligand-
binding domain of the estrogen receptor (ERTM) at the carboxy ter-
minus to facilitate functional control. (B) EKLF expression increases
with tamoxifen induction. Crude nuclear extracts were prepared from
J2eeklf/irGFP (lane 1) and J2eeklf/ flEKLF cells after 48 h in growth
media with varied tamoxifen concentrations (0, 10	3, 10	2, 10	1, 101,
102, and 103, lanes 2 to 8, respectively) and analyzed by immunoblot-
ting with HA-specific antisera. To test for loading equivalency, the blot
was stripped and reprobed with anti-PCNA antibody. (C) An increase
in maj transcripts correlates with increasing EKLF expression. Total
RNA was isolated from the J2eeklf/flEKLF cells and subjected to
RPA, utilizing maj and -globin antisense riboprobes.
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a clonal population of J2eeklf cells. After exposure and
expansion in growth media, GFP J2eeklf cells were selected
by FACS, and the structural integrity of the integrated retro-
viral genome was confirmed by Southern analysis (data not
shown).
To assess expression of the EKLF chimeric protein, nuclear
lysates from the irGFP- and EKLFirGFP-transduced popula-
tions were examined by immunoblot analysis utilizing HA-
specific antisera. Detectable levels of an immunoreactive band
of the correct molecular weight were present only in EKLF-
transduced cells (Fig. 1B, compare lane 1 to lanes 2 to 8). To
determine the dose of tamoxifen for the optimal EKLF nuclear
concentration, J2eeklf/flEKLF cells were cultured in the ab-
sence of tamoxifen for 24 h and subsequently switched into
media containing increasing concentrations of tamoxifen. Af-
ter an additional 36 h in culture, nuclear extracts and total
RNA were isolated from each growth condition. A small
amount of immunoreactive protein was observed in the nu-
cleus in the absence of tamoxifen induction (Fig. 1B, lane 2),
which probably reflects some contamination of nuclear extracts
with cytosolic material. However, an incremental increase in
EKLF detection occurred at 101 to 103 nM tamoxifen induc-
tions (lanes 5 to 7). In contrast, no further increase in EKLF
expression was observed in cell populations treated with 103
nM concentrations (lane 8).
To determine what level of EKLF was required for -globin
gene expression, RPA were used to measure maj transcripts.
In each sample, -globin transcripts were measured to exclude
differences in RNA concentration. After induction with tamox-
ifen, an increase in -globin expression, over -globin expres-
sion, was detected between concentrations of 100 and 102 nM
(Fig. 1C, lanes 2 to 7). This increase correlated with EKLF
expression (compare Fig. 1B and C). Moreover, we observed a
proportionate decrease in the - and -globin transcripts in
cells treated with tamoxifen concentrations of 103 nM (lane
8). Based on these observations, all subsequent studies were
performed at a 102 nM concentration of tamoxifen.
Human EKLF restores an open chromatin structure at the
-globin promoter in J2eeklf cells. At the murine maj pro-
moter, a known developmentally specific and tissue-specific
hypersensitivity site (HS) has been located approximately 100
bp upstream of the transcriptional start site (16). Studies with
EKLF null embryos demonstrated not only a specific loss of
-gene transcription but also a loss of the HS (72). To deter-
mine if a similar dependence occurred in J2eeklf cells, nuclei
from tamoxifen-induced J2eeklf/flEKLF cells were treated
with increasing amounts of DNase I. As a control, nuclei from
untreated cells (no tamoxifen) were treated in the same man-
ner. Genomic DNA was isolated from each reaction, and the
HS pattern was determined by Southern blotting, using an
internal probe to the 7.0-kb restriction fragment (R1) that
encompasses the maj promoter region (Fig. 2A). As shown in
Fig. 2B (top left panel), no HS was detected in the absence of
EKLF expression. However, a 1.3-kb fragment was observed
with EKLF expression that is identical to the wild-type HS
pattern previously described (Fig. 2B, top right panel) (34). To
control for the possibility that the observed DNase I sensitivity
was not a result of nonspecific induction by tamoxifen, the HS
patterns were determined for the erythroid-specific ala-s and
non-erythroid-specific myoD (data not shown) genes. As rep-
resented by the pattern revealed using an ala-s promoter probe
(Fig. 2B, bottom panels) (64), HS patterns of EKLF-indepen-
dent genes were not altered by tamoxifen.
A small carboxy-terminal domain of EKLF is sufficient to
remodel chromatin in vivo. Establishment of an open pro-
moter structure and rescue of maj expression by flEKLF in
the J2eeklf cell line permitted us to explore the structure-
function relationships of various domains of EKLF in the con-
text of the endogenous locus. To delineate these functions, we
prepared a series of NH2-terminal mutants of EKLF (Fig. 3A).
The selection of deletions was based, in part, on domains
previously defined in reporter assays and protein-protein in-
FIG. 2. Expression of the EKLF cDNA results in restoration of
DNase I hypersensitivity at the maj promoter. (A) Schematic repre-
sentation of HS formation at the maj promoter. (B) Induction of
DNase I hypersensitivity by tamoxifen treatment of J2eeklf/flEKLF
cells. Cells were cultured for 48 h in the absence (	) or presence ()
of tamoxifen. Nuclei were isolated and exposed to increasing concen-
trations of DNase I as previously described. To determine DNase
sensitivity of maj, DNA was harvested, digested with EcoRI, and
probed with a maj promoter-specific probe. For DNase sensitivity of
ala-s, DNA was digested with BamHI and probed with an ala-s pro-
moter-specific probe. The DNase I concentration is 0 in the first lane
of each panel and increases as shown by the shaded triangle. The
autoradiographs are representative of three independent experiments.
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teraction defined in vitro (4, 11, 37, 75, 76). Although each
construct contained the native DNA binding domain of EKLF,
additional analysis was performed to determine if the NH2-
terminal truncations altered binding affinity in EMSA. As
shown in a representative EMSA (Fig. 3B), recombinant forms
of all mutants bound in a similar fashion to a maj CACC
element-encoding probe compared to flEKLF.
Subsequently a series of J2eeklf cell lines expressing these
mutants was generated using the retrovirus-mediated expres-
sion strategy described above for flEKLF (Fig. 1A and 4A). To
determine if comparable levels of EKLF in the nucleus were
obtained in induced cells for each construct, Western analysis
was performed on nuclear extracts collected after 48 h of
growth in 100 nM tamoxifen. As shown in the representative
immunoblot, an equivalent EKLF signal was found in each
nuclear extract, when corrected for expression of p38, a ubiq-
uitously expressed control (Fig. 4B). To determine the effect of
the NH2-terminal deletions on formation of HS, nuclei of
induced cells for each mutant were incubated with increasing
amounts of DNase I (Fig. 4C). Contrary to in vitro chromatin
remodeling assays (37), the analysis of the HS pattern in
J2eeklf cells expressing 253EKLF demonstrated a pattern
similar to that previously observed for J2eeklf null cells (Fig.
2B). In contrast, studies of cells expressing 221EKLF and
164EKLF showed an HS pattern similar to that observed
with flEKLF. These results suggest that EKLF sequence be-
tween amino acids 221 and 253 is essential for open chroma-
tin configuration, as measured by DNase I hypersensitivity.
To confirm that nuclear localization was not altered by the
NH2-terminal truncations, immunofluorescence microscopy of
transfected cells was performed, and intense nuclear localiza-
tion was observed for all mutant proteins (data not shown).
The DNA binding domain of EKLF is sufficient for BRG1
interaction in vivo. An SWI/SNF complex, E-RC1, has been
demonstrated to mediate chromatin remodeling by murine
EKLF in vitro (4). E-RC1 and its central catalytic component,
BRG1, interact directly with the DNA binding domain of
EKLF, and this interaction is sufficient to remodel a chroma-
tinized -promoter template (37). To extend these studies and
to determine if a larger domain was required in the context of
human EKLF, in vitro binding studies were performed. Re-
combinant forms of each mutant EKLF molecule fused in
frame with a GST polypeptide were prepared in bacteria and
bound to glutathione Sepharose beads. Each preparation was
assayed for its ability to bind 35S-methionine-labeled BRG1.
As seen in a representative autoradiograph, a BRG1 signal was
present for each corresponding GST-EKLF fusion but not for
GST alone (Fig. 5A). Importantly, BRG1 interacted with
253EKLF, which contained all the sequences required by
murine EKLF to remodel in vitro-chromatinized -globin tem-
plates (37).
To determine if a similar requirement occurred in vivo, we
studied the abilities of flEKLF and the mutant EKLF mole-
cules to interact with BRG1 in SW13 cells, a cell line that lacks
endogenous BRG1 (24). SW13 cells were cotransfected with
vectors expressing BRG1 and individual mutants and propa-
gated for 48 h, and nuclear extracts were prepared. Immuno-
precipitation of HA-tagged flEKLF with anti-HA antibody re-
sulted in coprecipitation of BRG1 (Fig. 5B). Similar results
were observed with 162EKLF and 221EKLF. Moreover,
BRG1 could coprecipitate with 253EKLF, suggesting that the
observed in vitro interaction between the DNA binding do-
main of EKLF and BRG1 occurs in vivo.
An internal domain of EKLF is sufficient to activate -glo-
bin-specific expression in J2eeklf cells. Based on prior struc-
tural analysis of EKLF, the activation domain of EKLF should
reside in sequences upstream of the 221–253 region (11, 54).
Our HS studies suggested that the in vivo transcriptional and
chromatin remodeling activities of EKLF are separable. To
test this hypothesis, transcriptional activity for each mutant was
measured and correlated with its chromatin remodeling prop-
erties. Concurrent with HS assays, RNA of the induced sam-
ples was isolated for RPA analysis, using  and maj ribo-
probes. As anticipated, no significant level of maj transcript
was detected in the 253EKLF cells (Fig. 6A). In contrast,
expression of the 221EKLF polypeptide resulted in a small
but appreciable (threefold) increase in gene transcripts. How-
ever, examination of 164EKLF-expressing cells revealed lev-
els of maj transcripts that paralleled flEKLF expression,
when compared to -globin signal to correct for gel loading
differences.
Human and murine EKLF share a high degree of identity at
FIG. 3. Generation of a series of -CACC-binding hEKLF mu-
tants. (A) Schematic representation of EKLF mutants tested. NH2-
terminal mutants were chosen based on functional properties of EKLF
defined in in vitro studies. Construction of these mutants is detailed in
Materials and Methods. Above the diagram are the known protein-
protein interactions of EKLF. The dotted area indicates the zinc finger
DNA binding domain. (B) All amino-terminal mutants of EKLF bind
the cognate maj CACC motif. Equal amounts of bacterially expressed
recombinant EKLF polypeptides were incubated with a 32P-radiola-
beled -CACC probe for 30 min at room temperature. The products of
this reaction were electrophoresed through a 4% polyacrylamide gel
and then gel dried and subjected to autoradiography. The representa-
tive autoradiograph shows an electrophoretic mobility shift assay for
each mutant.
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the level of primary polypeptide structure (8, 66). Similar to
the findings at the endogenous locus (Fig. 6A), a recent study
demonstrated that an internal domain of murine EKLF was
capable of activating a transient -promoter reporter construct
in erythroid cells (54). Although the transiently transfected
constructs may acquire some degree of chromatin structure,
they predominantly measure the transactivation potential of
protein domains. To determine the relative abilities of hEKLF
and the COOH mutants described above to induce transacti-
vation in this context, expression plasmids encoding flEKLF
or the mutants were cotransfected into K562 cells with the
HS2Luc reporter plasmid (Fig. 6B). K562 cells provide a
favorable background for these studies based on their ery-
throid properties and lack of significant endogenous EKLF
activity (23). The HS2Luc reporter construct contained a
300-bp -promoter fragment flanked by the hypersensitivity
site 2 (HS2) enhancer region of the locus control region and a
luciferase reporter gene. Cotransfection of the reporter plas-
mid with the DNA binding domain mutant, 253EKLF, failed
to activate the reporter above the control. Expression of the in
vivo chromatin remodeling mutant, 221EKLF, resulted in
low-level reporter gene expression, similar to that observed at
the endogenous locus. In contrast, addition of another 60 res-
idues, 164EKLF, resulted in promoter activation that was
comparable to that observed with flEKLF. These results sug-
gested that these assays recapitulate the transactivation prop-
erties of hEKLF that we observed at the endogenous pro-
moter.
In vivo activation of the -globin gene by human EKLF is
BRG1 dependent. SWI/SNF complexes have been implicated
not only in chromatin remodeling but also in transcriptional
FIG. 4. The DNA binding domain is required but is not sufficient for chromatin remodeling at the maj globin promoter. (A) Schematic
diagram of flEKLF retrovirus and derivative mutants used to stably transduce J2eeklf cells. (B) Retrovirus-mediated transfer into J2eeklf cells
results in comparable levels of EKLF transgene expression. Nuclear extracts were prepared from individual pools of J2eeklf cells transduced with
EKLF mutant retroviruses after 48 h of culturing in the presence of tamoxifen. Equal amounts of protein were separated on SDS-PAGE gels,
blotted, and probed with HA-specific antisera. Blots were subsequently stripped and reprobed with p38-specific antisera to confirm equivalency
of gel loading. (C) Induction of DNase I hypersensitivity at the -globin promoter requires a large carboxy-terminal domain. Cells expressing each
EKLF mutant were cultured for 48 h in the presence of tamoxifen. Nuclei were isolated and exposed to increasing concentrations of DNase I as
previously described. DNA was harvested, digested with EcoRI, and probed with a maj-specific probe. The DNase I concentration is 0 in the first
lane of each panel and increases as shown by the shaded triangle. The autoradiograph is representative of several independent experiments.
FIG. 5. BRG1, the core component of the SWI/SNF complex E-
RC1, requires the zinc finger region of hEKLF for maximal interaction
in vitro and in vivo. (A) The hEKLF DNA binding region directly
interacts with BRG1. EKLF mutant polypeptides fused to GST or GST
protein alone bound to glutathione beads was incubated with equal
amounts of in vitro-translated 35S-methionine-labeled BRG1. Beads
were extensively washed, and bound protein was revealed by SDS-
PAGE and fluorography. (B) A similar pattern of EKLF-BRG1 inter-
action is observed in vivo. SW13 cells were cotransfected with BRG1-
and EKLF-expressing plasmids. Nuclear extracts were prepared 48 h
posttransfection and incubated with HA-epitope tag antisera. Inter-
acting proteins were precipitated, and the products were separated by
SDS-PAGE. After blotting to nylon filters was done, BRG1-specific
antiserum was utilized to detect the presence of EKLF-BRG1 specific
interactions.
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activation (13, 74). To determine the role of BRG1 in EKLF-
specific transactivation, we established an EKLF transactiva-
tion assay in the SW13 cell line. These cells are particularly
helpful in addressing this issue as they lack functional BRG1
expression (24). Activation assays were done identically to
those performed with K562 cells (Fig. 6B), except that flEKLF
and EKLF mutants were tested in the presence of either ex-
ogenous expressed wild-type (wt) BRG1 or a derivative BRG1
deletion mutant. Expression of flEKLF and mutants with the
hBRG1 plasmid failed to activate -promoter activity (Fig.
7A, open bars). However, consistent augmentation of pro-
moter activation occurred with coexpression of flEKLF with
wt hBRG1. Similarly, coexpression of 164EKLF and BRG1
resulted in promoter activation. In contrast, expression of
221EKLF or 253EKLF with wt BRG1 failed to significant-
ly activate the target promoter. These results suggested that
BRG1 is required for EKLF-dependent transactivation.
Based on these findings and those demonstrating BRG1
dependency on a reconstituted chromatinized template (4), we
anticipated that BRG1-dependent, EKLF-mediated transacti-
vation occurs at the endogenous -globin promoter. To ad-
dress this issue, we adapted the J2eeklf system to coexpress
flEKLF with a dominant-negative mutant of BRG1 (DN-
BRG1) and determined its effect on maj expression. The
DN-BRG1 mutant carried an altered ATPase activity site,
which has been shown to significantly attenuate wt BRG1 ac-
tivity in vivo (21). To allow coordinate induction of DN-BRG1
and flEKLF activities, the DN-BRG1 molecule was fused to
the ER domain in a fashion similar to that described for
flEKLF. A J2eeklf line was produced that demonstrated ta-
moxifen-dependent nuclear localization of both molecules by
immunoblotting (data not shown). As shown in a representa-
tive autoradiograph, expression of the transdominant mutant
resulted in significant reduction of EKLF-dependent -globin
gene activation (Fig. 7B, compare lanes 2 and 3). In contrast,
expression of DN-BRG1 did not affect  or h1 transcripts,
suggesting that the observed effect on the maj gene was spe-
cific.
DISCUSSION
Efforts to explore many of the molecular mechanisms un-
derpinning developmentally specific transcription in vivo have
been hampered by a lack of suitable models that evaluate the
physiological relevance of interactions defined in vitro. Here,
we report complementary biochemical and genetic analyses
that define the chromatin remodeling and transactivation do-
mains of EKLF in definitive erythroid cells. We have used the
J2eeklf cell line to characterize the functional domains of
EKLF in the context of the endogenous -globin gene. This
approach avoids deficiencies inherent to in vitro transcription
and transient reporter-based assays, including the nonchromo-
somal nature of the DNA template and the inability to assess
the effects of DNA replication. It minimizes dependency on
transgenic constructs, where copy number and chromosomal
position are variable. This is particularly important for studies
of the -globin locus, based on differences in the phenotypes of
cis-acting mutations generated at the endogenous locus com-
pared to single- or multiple-copy transgene constructs (10, 26,
32).
Numerous mechanisms of action have been ascribed to
DNA-binding factors, including modulation of chromatin and
DNA architecture, interaction with nuclear structural proteins,
and recruitment and/or regulation of components of the basal
FIG. 6. An internal domain of hEKLF is sufficient to activate -globin gene expression to wild-type levels. (A) Addition of amino acids 164 to
221 is sufficient to confer wild-type activation potential on the DNA binding (253EKLF) and chromatin remodeling (221EKLF) domains of
EKLF. RNA was harvested from J2eeklf clones expressing varying EKLF mutant moieties at 48 h post-tamoxifen induction. RPA was performed
utilizing maj and  riboprobes. The numbers underneath the panel represent the mean fold induction of the / ratio for each construct assayed,
using three independent experiments and the activity in cells transduced by vector alone as baseline. (B) The identical domain of hEKLF activates
a -promoter-regulated reporter gene in transient assays. EKLF mutant constructs lacking the ER element were subcloned into a mammalian
expression vector. These constructs were cotransfected individually into K562 cells, along with a human -globin promoter construct, HS2Luc,
and a Renilla luciferase control plasmid. Luciferase activity was determined by luminometry 48 h posttransfection. Fold activation of each construct
is represented with respect to a control transfection of HS2Luc and the empty expression vector. The effect on HS2 luciferase activity for each
hEKLF construct was measured in six separate assays of three independent transfections. The results of the Renilla luciferase analysis were utilized
to correct for variation in transfection efficiency.
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transcriptional machinery (38, 45). Many factors have domains
with complementary or opposing functions, their activity being
dependent on promoter context (29). Indeed, studies of EKLF,
utilizing reporter constructs, suggest that optimal function oc-
curs only in the context of the -globin promoter (5). Thus, a
focused analysis of a trans activator at an established target
locus provides significant advantages for dissection of the steps
necessary for transcriptional activation in vivo. Complemen-
tary experiments utilizing transiently transfected reporter con-
structs have demonstrated that EKLF is a modular protein
consisting of a carboxy-terminal DNA binding domain linked
to a proline-rich transactivation domain (9, 49). Furthermore,
elegant studies by Emerson and colleagues have shown that the
zinc finger DNA binding domain of murine EKLF is sufficient
to induce complete remodeling of a nucleosomal loaded -pro-
moter template, through recruitment of a multimeric SWI/
SNF complex, E-RC1 (4). In the context of the native chro-
matin locus, we demonstrate that EKLF-dependent chromatin
remodeling requires the defined DNA binding domain identi-
fied in vitro (37) as well as an adjacent region of approximately
35 amino acids (Fig. 4C). For EKLF-dependent activation, a
second internal domain of hEKLF is sufficient for gene acti-
vation to levels observed with the full-length molecule (Fig.
6A). In addition to delineating this internal region, we provide
evidence that the SWI/SNF factor BRG1 is required for its
activity at the endogenous -globin gene.
Several possibilities could account for the discrepancy be-
tween the in vitro and in vivo chromatin remodeling activities
of EKLF. One simple explanation is that 253EKLF has al-
tered nuclear localization and/or DNA binding. However, this
molecule contains a functional nuclear localization signal (1)
and is detected in the nucleus by cell fractionation and immu-
nofluorescence studies (Fig. 4B and data not shown). More-
over, in electrophoretic mobility shift assays, this domain
showed an affinity for the cognate -CACC motif similar to
that of the full-length polypeptide (Fig. 3B). A second possi-
bility is that amino acid sequence variation between human
and murine EKLF may result in different affinities for the
BRG1 subunit of E-RC1. Although the definitive structures of
these molecules are not available, the primary sequences of
murine and human EKLF are highly homologous. A third
possible explanation is that the additional sequence may be
required for a stable interaction between hEKLF and BRG1.
Indeed, recent studies of the interaction between the C/EBP
transactivator and hBRM, a closely related homologue of
hBRG1, demonstrate that sequences outside the binding do-
main influence the relative affinity of the interaction (42). In
contrast, no appreciable difference in affinity for BRG1 was
observed between 253EKLF and other EKLF constructs
tested in vitro or in vivo (Fig. 5).
Why is the larger 221EKLF polypeptide required for re-
modeling in vivo? The most likely explanation is that a fac-
tor(s) not present in the in vitro reconstitution assays is re-
quired for the establishment and/or maintenance of the open
chromatin configuration induced in vivo by EKLF. A highly
attractive candidate for this additional factor would be a his-
tone acetyl transferase, given the postulated role of histone
acetylation in stabilization of SWI/SNF-induced changes in
native chromatin (17, 22, 43). Indeed, previous studies have
demonstrated an interaction between the carboxy-terminal
zinc finger domain of murine EKLF and the coactivator CBP,
a potent histone acetyl transferase (12, 75). This domain is
encompassed completely in our 253EKLF construct. Al-
though the possible role of CBP in modulating histone acety-
lation of the endogenous -promoter has not been explored,
Chen and Bieker have demonstrated that CBP interacts with,
and acetylates, the carboxy-terminal zinc finger domain of mu-
rine EKLF, with a consequent increase in the ability to recruit
BRG1 (12). We have shown that CBP interacts specifically
with 253EKLF human polypeptide and does not require the
FIG. 7. BRG1 is required for EKLF function in vivo. (A) BRG1 is
required for transactivation of an EKLF-dependent promoter. Plas-
mids expressing full-length EKLF or amino-terminal mutants of EKLF
were cotransfected into SW13 cells with either wt BRG1-expressing
plasmid (black bars) or the derivative pBRG1 alone (white bars). In
addition, each transfection contained the HS2Luc reporter construct.
Luciferase activity was determined by luminometry 48 h posttransfec-
tion. Fold activation of each construct is represented with respect to a
control transfection of HS2Luc and the empty expression vector. The
graph reflects HS2 luciferase activation for each hEKLF construct,
measured in six separate assays of three independent transfections. (B)
Dominant-negative form of BRG1 (DN-BRG1) represses specifically
EKLF-dependent transcription in fetal erythroblasts. J2eeklf/flEKLF-
irGFP/DN-BRG1-irYFP cells were generated in a fashion similar to
that described for J2eeklf/flEKLF-irGFP cells (see Fig. 1 and Mate-
rial and Methods). Total cellular RNA was harvested 48 h post-tamox-
ifen induction, and RPA was performed using maj, hl, and  ribo-
probes. The autoradiograph represents the level of each transcript
detected for the J2eeklf lines. Asterisks, nonspecific bands.
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amino acid 221 to 253 region for effective binding (S.P., S.M.J.,
and J.M.C., unpublished data). Thus, it is unlikely that CBP is
the missing factor that explains the chromatin remodeling ac-
tivity of the amino acid 221 to 253 domain. However, it does
not exclude an indirect role of a CBP-EKLF interaction in
coactivator recruitment or in the maintenance of an open chro-
matin configuration. Given the multisubunit composition of
SWI/SNF complexes and the increasing list of chromatin re-
modeling complexes being described, we propose that an ad-
ditional factor(s) binds the upstream domain of EKLF and
facilitates chromatin remodeling in vivo. A focused search for
this factor is now feasible with the tools generated by this
study.
The ability to coprecipitate EKLF and BRG1 provides in-
sight into the mechanism of gene activation, specifically the
timing of the initial interaction between the SWI/SNF complex
and EKLF. Previous studies of activator interactions with SWI/
SNF complexes have provided evidence for two models (60). It
is possible that a factor can bind its DNA element, acting as a
docking site for the remodeling complex. Alternatively, the
activator-SWI/SNF interaction may occur in solution, with the
DNA-binding domain directing chromatin remodeling at a
later step. In the case of EKLF, prior studies demonstrated
that EKLF binds nucleosome-loaded templates poorly in the
absence of BRG1 (4). Our experiments extend this observation
by demonstrating that EKLF binds BRG1 in vivo in the ab-
sence of an available DNA binding element (Fig. 5B), support-
ing the second model of EKLF-mediated recruitment of E-
RC1.
It is interesting that expression of the 221EKLF construct
results in a modest increase in transcription (Fig. 6A). This
observation is consistent with the concept that when the -glo-
bin promoter becomes accessible, low-level transcription can
occur. However, recruitment of other cofactors, through inter-
actions with the EKLF upstream transactivation domain (ami-
no acids 164 to 221), is required for high-level activation. These
observations are concordant with the “poised” promoter
model suggested by in vitro transcription assays and studies of
stress-inducible promoters (3, 30, 31, 55). Indeed, recent stud-
ies of GAL4-mediated recruitment of the SAGA remodeling
complex suggest that reorganization of the promoter chroma-
tin structure facilitates recruitment of the RNA polymerase
complex (7, 44). Thus, the dependency of -gene expression on
the BRG1-hEKLF interaction we observed both in transient
assays and at the endogenous locus (Fig. 7) suggests that E-
RC1 may facilitate recruitment of the basal transcriptional
machinery to the open -globin promoter in vivo. Ongoing
studies utilizing chromatin immunoprecipitation and fine map-
ping with nucleases will allow us to determine precisely the
factors required at the promoter at each step of the activation
process. Moreover, the temporal relationships with GATA-1
and Sp1, -promoter-binding factors which have been shown
previously to interact with EKLF (48), can be explored.
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